drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01100 | DB01142 | 1,568 | 1,264 | [
"DDInter1470",
"DDInter593"
] | Pimozide | Doxepin | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Major | 2 | [
[
[
1568,
25,
1264
]
],
[
[
1568,
64,
401
],
[
401,
24,
1264
]
],
[
[
1568,
63,
832
],
[
832,
24,
1264
]
],
[
[
1568,
24,
649
],
[
649,
... | [
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may ... | Pimozide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may c... |
DB00092 | DB00515 | 58 | 589 | [
"DDInter40",
"DDInter387"
] | Alefacept | Cisplatin | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Moderate | 1 | [
[
[
58,
24,
589
]
],
[
[
58,
24,
949
],
[
949,
63,
589
]
],
[
[
58,
24,
168
],
[
168,
24,
589
]
],
[
[
58,
23,
1461
],
[
1461,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid anti... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Alefacept may ... |
DB01197 | DB01309 | 1,603 | 1,254 | [
"DDInter292",
"DDInter933"
] | Captopril | Insulin glulisine | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
1603,
24,
1254
]
],
[
[
1603,
64,
1621
],
[
1621,
23,
1254
]
],
[
[
1603,
25,
948
],
[
948,
62,
1254
]
],
[
[
1603,
63,
167
],
[
167,
... | [
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Captopril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
... | Captopril may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Captopril may lead to a major life threatening interaction when taken with Potassium gluconate and Potassiu... |
DB04845 | DB08880 | 309 | 1,510 | [
"DDInter1001",
"DDInter1771"
] | Ixabepilone | Teriflunomide | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
309,
25,
1510
]
],
[
[
309,
63,
1461
],
[
1461,
23,
1510
]
],
[
[
309,
24,
129
],
[
129,
63,
1510
]
],
[
[
309,
24,
1136
],
[
1136,
... | [
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitami... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enz... |
DB00365 | DB01268 | 839 | 1,151 | [
"DDInter842",
"DDInter1731"
] | Grepafloxacin | Sunitinib | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Major | 2 | [
[
[
839,
25,
1151
]
],
[
[
839,
23,
112
],
[
112,
23,
1151
]
],
[
[
839,
25,
1148
],
[
1148,
24,
1151
]
],
[
[
839,
25,
1250
],
[
1250,
... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Grepafloxacin may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline... |
DB00766 | DB08870 | 1,675 | 850 | [
"DDInter394",
"DDInter228"
] | Clavulanic acid | Brentuximab vedotin | Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with [Amoxicillin] or [Ticarcillin] to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible bacterial infections. Clavulanic acid is derived from the organism Streptomyces... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1675,
24,
850
]
],
[
[
1675,
63,
267
],
[
267,
24,
850
]
],
[
[
1675,
24,
384
],
[
384,
63,
850
]
],
[
[
1675,
25,
1510
],
[
1510,
... | [
[
[
"Clavulanic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Clavulanic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexo... | Clavulanic acid may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Clavulanic acid may cause a moderate interaction that could exacerbate diseases when taken with Id... |
DB00526 | DB00762 | 1,555 | 613 | [
"DDInter1355",
"DDInter973"
] | Oxaliplatin | Irinotecan | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Moderate | 1 | [
[
[
1555,
24,
613
]
],
[
[
1555,
25,
869
],
[
869,
63,
613
]
],
[
[
1555,
6,
10659
],
[
10659,
45,
613
]
],
[
[
1555,
25,
945
],
[
945,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan... | Oxaliplatin may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Oxaliplatin (Compound) binds SLC22A3 (Gene) and SLC22A3 (Gene) is bound by Irinotecan (Compound)
Oxaliplatin may lead to a major... |
DB00279 | DB01576 | 1,152 | 93 | [
"DDInter1074",
"DDInter526"
] | Liothyronine | Dextroamphetamine | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Dextroamphetamine is the dextrorotatory enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label]. | Moderate | 1 | [
[
[
1152,
24,
93
]
],
[
[
1152,
63,
73
],
[
73,
1,
93
]
],
[
[
1152,
1,
11215
],
[
11215,
40,
93
]
],
[
[
1152,
63,
80
],
[
80,
40,
... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextroamphetamine"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
... | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) resembles Dextroamphetamine (Compound)
Liothyronine (Compound) resembles L-Phenylalanine (Compound) and L-Phenylalanine (Compound) resembles Dextroamphetamine (Compound)
Liothyronine may c... |
DB08885 | DB08895 | 363 | 976 | [
"DDInter33",
"DDInter1825"
] | Aflibercept | Tofacitinib | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Dalt... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
363,
25,
976
]
],
[
[
363,
24,
200
],
[
200,
63,
976
]
],
[
[
363,
63,
1430
],
[
1430,
24,
976
]
],
[
[
363,
64,
1011
],
[
1011,
... | [
[
[
"Aflibercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"C... | Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Sipule... |
DB00770 | DB01240 | 642 | 885 | [
"DDInter55",
"DDInter657"
] | Alprostadil | Epoprostenol | Alprostadil is a chemically-identical synthetic form of prostaglandin E1 (PGE1), a potent vasodilator produced endogenously. In 1996, the FDA approved the use of alprostadil, administered either with an intracavernosal injection or an intraurethral suppository, for the treatment of erectile dysfunction, and it is used ... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
642,
24,
885
]
],
[
[
642,
40,
11421
],
[
11421,
40,
885
]
],
[
[
642,
63,
1061
],
[
1061,
1,
885
]
],
[
[
642,
6,
9885
],
[
9885,
... | [
[
[
"Alprostadil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Alprostadil",
"{u} (Compound) resembles {v} (Compound)",
"Dinoprost Tromethamine"
],
[
"Dinoprost Tromethamine",
... | Alprostadil (Compound) resembles Dinoprost Tromethamine (Compound) and Dinoprost Tromethamine (Compound) resembles Epoprostenol (Compound)
Alprostadil may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Alprostadil (C... |
DB00226 | DB00388 | 1,000 | 1,636 | [
"DDInter845",
"DDInter1453"
] | Guanadrel | Phenylephrine | Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Moderate | 1 | [
[
[
1000,
24,
1636
]
],
[
[
1000,
24,
874
],
[
874,
40,
1636
]
],
[
[
1000,
24,
1148
],
[
1148,
63,
1636
]
],
[
[
1000,
63,
73
],
[
73,
... | [
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
... | Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine (Compound) resembles Phenylephrine (Compound)
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction tha... |
DB00069 | DB08895 | 367 | 976 | [
"DDInter946",
"DDInter1825"
] | Interferon alfacon-1 | Tofacitinib | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
367,
25,
976
]
],
[
[
367,
25,
534
],
[
534,
24,
976
]
],
[
[
367,
24,
1430
],
[
1430,
24,
976
]
],
[
[
367,
24,
810
],
[
810,
6... | [
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramad... | Interferon alfacon-1 may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Si... |
DB09049 | DB14575 | 1,135 | 733 | [
"DDInter1261",
"DDInter674"
] | Naloxegol | Eslicarbazepine | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
1135,
24,
733
]
],
[
[
1135,
63,
1101
],
[
1101,
23,
733
]
],
[
[
1135,
62,
1491
],
[
1491,
24,
733
]
],
[
[
1135,
25,
351
],
[
351,
... | [
[
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[... | Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin and Midost... |
DB00455 | DB11932 | 1,601 | 327 | [
"DDInter1091",
"DDInter3"
] | Loratadine | Abametapir (topical) | Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations. | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
1601,
24,
327
]
],
[
[
1601,
24,
283
],
[
283,
63,
327
]
],
[
[
1601,
24,
1478
],
[
1478,
24,
327
]
],
[
[
1601,
24,
283
],
[
283,
... | [
[
[
"Loratadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Loratadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
... | Loratadine may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Loratadine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Loratadine... |
DB06603 | DB15091 | 39 | 676 | [
"DDInter1387",
"DDInter1901"
] | Panobinostat | Upadacitinib | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
39,
25,
676
]
],
[
[
39,
24,
1430
],
[
1430,
24,
676
]
],
[
[
39,
63,
1249
],
[
1249,
24,
676
]
],
[
[
39,
25,
283
],
[
283,
24,... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Si... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin a... |
DB00209 | DB00434 | 352 | 13 | [
"DDInter1886",
"DDInter459"
] | Trospium | Cyproheptadine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
352,
24,
13
]
],
[
[
352,
24,
104
],
[
104,
63,
13
]
],
[
[
352,
24,
1302
],
[
1302,
24,
13
]
],
[
[
352,
40,
11286
],
[
11286,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and... |
DB00214 | DB00581 | 1,028 | 355 | [
"DDInter1836",
"DDInter1018"
] | Torasemide | Lactulose | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Moderate | 1 | [
[
[
1028,
24,
355
]
],
[
[
1028,
25,
416
],
[
416,
40,
355
]
],
[
[
1028,
24,
1647
],
[
1647,
1,
355
]
],
[
[
1028,
21,
28722
],
[
28722,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
]
],
[
[
"Torasemide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
... | Torasemide may lead to a major life threatening interaction when taken with Kanamycin and Kanamycin (Compound) resembles Lactulose (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose (Compound) resembles Lactulose (Compound)
Torasemide (Compound) c... |
DB00586 | DB09134 | 1,512 | 1,552 | [
"DDInter537",
"DDInter966"
] | Diclofenac | Ioversol | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Major | 2 | [
[
[
1512,
25,
1552
]
],
[
[
1512,
24,
33
],
[
33,
24,
1552
]
],
[
[
1512,
63,
17
],
[
17,
24,
1552
]
],
[
[
1512,
24,
242
],
[
242,
... | [
[
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may... |
DB00004 | DB01610 | 669 | 248 | [
"DDInter499",
"DDInter1912"
] | Denileukin diftitox | Valganciclovir | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
669,
24,
248
]
],
[
[
669,
24,
563
],
[
563,
1,
248
]
],
[
[
669,
25,
676
],
[
676,
63,
248
]
],
[
[
669,
25,
770
],
[
770,
24,
... | [
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganci... | Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Denileukin diftitox may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interacti... |
DB09134 | DB13985 | 1,552 | 546 | [
"DDInter966",
"DDInter1108"
] | Ioversol | Lutetium Lu 177 dotatate | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Major | 2 | [
[
[
1552,
25,
546
]
],
[
[
1552,
64,
50
],
[
50,
24,
546
]
],
[
[
1552,
64,
629
],
[
629,
25,
546
]
],
[
[
1552,
64,
50
],
[
50,
24,... | [
[
[
"Ioversol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Ioversol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazin... | Ioversol may lead to a major life threatening interaction when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Ioversol may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to... |
DB00501 | DB00530 | 752 | 1,195 | [
"DDInter380",
"DDInter667"
] | Cimetidine | Erlotinib | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Moderate | 1 | [
[
[
752,
24,
1195
]
],
[
[
752,
63,
883
],
[
883,
40,
1195
]
],
[
[
752,
6,
7950
],
[
7950,
45,
1195
]
],
[
[
752,
18,
6351
],
[
6351,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
... | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Erlotinib (Compound)
Cimetidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Erlotinib (Compound)
Cimetidine (Compound) downregulates COTL1 (Gene) and COTL1 (Gene) is d... |
DB01177 | DB10276 | 77 | 1,624 | [
"DDInter904",
"DDInter1623"
] | Idarubicin | Rotavirus vaccine | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
77,
25,
1624
]
],
[
[
77,
63,
552
],
[
552,
25,
1624
]
],
[
[
77,
64,
770
],
[
770,
25,
1624
]
],
[
[
77,
74,
51
],
[
51,
25,
... | [
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Car... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Rotavirus vaccine
Idarubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a ma... |
DB00978 | DB09043 | 739 | 135 | [
"DDInter1084",
"DDInter36"
] | Lomefloxacin | Albiglutide | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
739,
24,
135
]
],
[
[
739,
64,
126
],
[
126,
23,
135
]
],
[
[
739,
63,
1647
],
[
1647,
23,
135
]
],
[
[
739,
64,
870
],
[
870,
2... | [
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Lomefloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfari... | Lomefloxacin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a min... |
DB00445 | DB12010 | 322 | 214 | [
"DDInter655",
"DDInter785"
] | Epirubicin | Fostamatinib | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
322,
24,
214
]
],
[
[
322,
25,
976
],
[
976,
24,
214
]
],
[
[
322,
24,
866
],
[
866,
24,
214
]
],
[
[
322,
35,
51
],
[
51,
24,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacit... | Epirubicin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib and Cobimetinib may ... |
DB00328 | DB00563 | 831 | 663 | [
"DDInter921",
"DDInter1174"
] | Indomethacin | Methotrexate | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Major | 2 | [
[
[
831,
25,
663
]
],
[
[
831,
10,
11591
],
[
11591,
44,
663
]
],
[
[
831,
6,
4973
],
[
4973,
45,
663
]
],
[
[
831,
18,
7840
],
[
7840,
... | [
[
[
"Indomethacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
]
],
[
[
"Indomethacin",
"{u} (Compound) palliates {v} (Disease)",
"ankylosing spondylitis"
],
[
"ankylosing spondylitis",
"{u} (Dise... | Indomethacin (Compound) palliates ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) is treated by Methotrexate (Compound)
Indomethacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Methotrexate (Compound)
Indomethacin (Compound) downregulates TIMELESS (Gene) and TIMELESS (Gene) is upreg... |
DB00008 | DB09276 | 491 | 381 | [
"DDInter1407",
"DDInter1682"
] | Peginterferon alfa-2a | Sodium aurothiomalate | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no valu... | Moderate | 1 | [
[
[
491,
24,
381
]
],
[
[
491,
24,
1683
],
[
1683,
24,
381
]
],
[
[
491,
24,
1480
],
[
1480,
63,
381
]
],
[
[
491,
63,
1057
],
[
1057,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases wh... |
DB00215 | DB00736 | 1,230 | 660 | [
"DDInter388",
"DDInter676"
] | Citalopram | Esomeprazole | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Major | 2 | [
[
[
1230,
25,
660
]
],
[
[
1230,
25,
1215
],
[
1215,
40,
660
]
],
[
[
1230,
6,
8374
],
[
8374,
45,
660
]
],
[
[
1230,
21,
28785
],
[
28785... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esomeprazole"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
... | Citalopram may lead to a major life threatening interaction when taken with Lansoprazole and Lansoprazole (Compound) resembles Esomeprazole (Compound)
Citalopram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Esomeprazole (Compound)
Citalopram (Compound) causes Muscle spasms (Side Effect) and Muscle spasm... |
DB00348 | DB00812 | 254 | 998 | [
"DDInter1300",
"DDInter1451"
] | Nitisinone | Phenylbutazone | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Moderate | 1 | [
[
[
254,
24,
998
]
],
[
[
254,
63,
576
],
[
576,
1,
998
]
],
[
[
254,
24,
804
],
[
804,
40,
998
]
],
[
[
254,
23,
307
],
[
307,
1,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Phenylbutazone (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone and Sulfinpyrazone (Compound) resembles Phenylbutazo... |
DB00041 | DB01005 | 1,648 | 995 | [
"DDInter38",
"DDInter894"
] | Aldesleukin | Hydroxyurea | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Moderate | 1 | [
[
[
1648,
24,
995
]
],
[
[
1648,
23,
1299
],
[
1299,
23,
995
]
],
[
[
1648,
23,
945
],
[
945,
62,
995
]
],
[
[
1648,
24,
1238
],
[
1238,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trovafloxacin"
],
... | Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Hydroxyurea
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and S... |
DB00035 | DB01222 | 1,314 | 617 | [
"DDInter507",
"DDInter246"
] | Desmopressin | Budesonide | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Major | 2 | [
[
[
1314,
25,
617
]
],
[
[
1314,
25,
1351
],
[
1351,
1,
617
]
],
[
[
1314,
21,
28719
],
[
28719,
60,
617
]
],
[
[
1314,
24,
1148
],
[
1148... | [
[
[
"Desmopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
]
],
[
[
"Desmopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flunisolide"
],
[
"Flunisolide",
... | Desmopressin may lead to a major life threatening interaction when taken with Flunisolide and Flunisolide (Compound) resembles Budesonide (Compound)
Desmopressin (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Budesonide (Compound)
Desmopressin may cause a moderate interaction that could exacer... |
DB00321 | DB00350 | 21 | 1,214 | [
"DDInter78",
"DDInter1226"
] | Amitriptyline | Minoxidil | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | Moderate | 1 | [
[
[
21,
24,
1214
]
],
[
[
21,
24,
530
],
[
530,
63,
1214
]
],
[
[
21,
25,
593
],
[
593,
63,
1214
]
],
[
[
21,
35,
1376
],
[
1376,
63... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil
Amitriptyline may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cau... |
DB12001 | DB15091 | 564 | 676 | [
"DDInter7",
"DDInter1901"
] | Abemaciclib | Upadacitinib | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
564,
25,
676
]
],
[
[
564,
63,
1430
],
[
1430,
24,
676
]
],
[
[
564,
24,
283
],
[
283,
24,
676
]
],
[
[
564,
24,
1654
],
[
1654,
... | [
[
[
"Abemaciclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipu... | Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib an... |
DB06772 | DB12095 | 310 | 179 | [
"DDInter259",
"DDInter1760"
] | Cabazitaxel | Telotristat ethyl | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
310,
24,
179
]
],
[
[
310,
63,
79
],
[
79,
24,
179
]
],
[
[
310,
24,
214
],
[
214,
24,
179
]
],
[
[
310,
25,
676
],
[
676,
63,
... | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
... | Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib a... |
DB00005 | DB00649 | 1,057 | 231 | [
"DDInter687",
"DDInter1710"
] | Etanercept | Stavudine | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | Moderate | 1 | [
[
[
1057,
24,
231
]
],
[
[
1057,
24,
1477
],
[
1477,
40,
231
]
],
[
[
1057,
25,
1083
],
[
1083,
40,
231
]
],
[
[
1057,
25,
139
],
[
139,
... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stavudine"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
],
[
... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine and Telbivudine (Compound) resembles Stavudine (Compound)
Etanercept may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine (Compound) resembles Stavudine (Compound)
Etanercept ... |
DB11126 | DB12455 | 900 | 933 | [
"DDInter276",
"DDInter1336"
] | Calcium gluconate | Omadacycline | Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injecti... | Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in ani... | Moderate | 1 | [
[
[
900,
24,
933
]
],
[
[
900,
63,
504
],
[
504,
24,
803
],
[
803,
24,
933
]
],
[
[
900,
63,
1586
],
[
1586,
63,
803
],
[
803,
24,
... | [
[
[
"Calcium gluconate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Calcium gluconate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochloro... | Calcium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium chloride and Calcium chloride may cause a moderate interaction that could exacerbate disea... |
DB00283 | DB00572 | 701 | 85 | [
"DDInter395",
"DDInter136"
] | Clemastine | Atropine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Moderate | 1 | [
[
[
701,
24,
85
]
],
[
[
701,
24,
19
],
[
19,
24,
85
]
],
[
[
701,
63,
357
],
[
357,
24,
85
]
],
[
[
701,
18,
4930
],
[
4930,
57,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Benzatropine and Benz... |
DB00619 | DB00776 | 1,419 | 1,335 | [
"DDInter909",
"DDInter1360"
] | Imatinib | Oxcarbazepine | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Moderate | 1 | [
[
[
1419,
24,
1335
]
],
[
[
1419,
25,
126
],
[
126,
1,
1335
]
],
[
[
1419,
24,
1264
],
[
1264,
63,
1335
]
],
[
[
1419,
64,
1236
],
[
1236,... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
... | Imatinib may lead to a major life threatening interaction when taken with Warfarin and Warfarin (Compound) resembles Oxcarbazepine (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when ... |
DB00026 | DB14881 | 1,184 | 180 | [
"DDInter94",
"DDInter1329"
] | Anakinra | Oliceridine | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1184,
24,
180
]
],
[
[
1184,
24,
36
],
[
36,
24,
180
]
],
[
[
1184,
25,
980
],
[
980,
24,
180
]
],
[
[
1184,
64,
1057
],
[
1057,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Anakinra may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a mod... |
DB00341 | DB08815 | 1,242 | 154 | [
"DDInter343",
"DDInter1104"
] | Cetirizine | Lurasidone | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
1242,
24,
154
]
],
[
[
1242,
21,
28963
],
[
28963,
60,
154
]
],
[
[
1242,
24,
1532
],
[
1532,
24,
154
]
],
[
[
1242,
74,
701
],
[
701,... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused b... | Cetirizine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Lurasidone (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
... |
DB00816 | DB11986 | 1,674 | 484 | [
"DDInter1346",
"DDInter648"
] | Orciprenaline | Entrectinib | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1674,
24,
484
]
],
[
[
1674,
24,
222
],
[
222,
23,
484
]
],
[
[
1674,
24,
1539
],
[
1539,
24,
484
]
],
[
[
1674,
63,
322
],
[
322,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and ... |
DB01181 | DB04946 | 1,532 | 924 | [
"DDInter906",
"DDInter907"
] | Ifosfamide | Iloperidone | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
1532,
24,
924
]
],
[
[
1532,
63,
1664
],
[
1664,
1,
924
]
],
[
[
1532,
24,
519
],
[
519,
40,
924
]
],
[
[
1532,
6,
21998
],
[
21998,
... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Iloperidone (Co... |
DB09078 | DB11642 | 1,228 | 938 | [
"DDInter1036",
"DDInter1480"
] | Lenvatinib | Pitolisant | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
1228,
24,
938
]
],
[
[
1228,
62,
112
],
[
112,
23,
938
]
],
[
[
1228,
63,
28
],
[
28,
24,
938
]
],
[
[
1228,
24,
927
],
[
927,
6... | [
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Lenvatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Lenvatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisac... |
DB06595 | DB14575 | 1,491 | 733 | [
"DDInter1214",
"DDInter674"
] | Midostaurin | Eslicarbazepine | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
1491,
24,
733
]
],
[
[
1491,
63,
1101
],
[
1101,
23,
733
]
],
[
[
1491,
63,
1264
],
[
1264,
24,
733
]
],
[
[
1491,
23,
1135
],
[
1135,... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxe... |
DB00224 | DB06595 | 215 | 1,491 | [
"DDInter917",
"DDInter1214"
] | Indinavir | Midostaurin | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
215,
25,
1491
]
],
[
[
215,
25,
1135
],
[
1135,
62,
1491
]
],
[
[
215,
24,
761
],
[
761,
24,
1491
]
],
[
[
215,
25,
1017
],
[
1017,
... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may ... | Indinavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a m... |
DB08896 | DB11718 | 292 | 927 | [
"DDInter1576",
"DDInter640"
] | Regorafenib | Encorafenib | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
292,
25,
927
]
],
[
[
292,
63,
372
],
[
372,
24,
927
]
],
[
[
292,
64,
998
],
[
998,
24,
927
]
],
[
[
292,
24,
1654
],
[
1654,
6... | [
[
[
"Regorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofar... | Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Regorafenib may lead to a major life threatening interaction when taken with Phenylbutazone and Phenylbutazo... |
DB01101 | DB08826 | 60 | 1,292 | [
"DDInter285",
"DDInter489"
] | Capecitabine | Deferiprone | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
60,
25,
1292
]
],
[
[
60,
21,
28759
],
[
28759,
60,
1292
]
],
[
[
60,
23,
1384
],
[
1384,
63,
1292
]
],
[
[
60,
23,
115
],
[
115,
... | [
[
[
"Capecitabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Capecitabine",
"{u} (Compound) causes {v} (Side Effect)",
"Connective tissue disorder"
],
[
"Connective tissue disorder",
"{... | Capecitabine (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Deferiprone (Compound)
Capecitabine may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacer... |
DB00191 | DB00912 | 73 | 473 | [
"DDInter1447",
"DDInter1581"
] | Phentermine | Repaglinide | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
73,
24,
473
]
],
[
[
73,
21,
28763
],
[
28763,
60,
473
]
],
[
[
73,
25,
551
],
[
551,
24,
473
]
],
[
[
73,
24,
216
],
[
216,
24,... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Phentermine",
"{u} (Compound) causes {v} (Side Effect)",
"Chest pain"
],
[
"Chest pain",
"{u} (Side Effect) is... | Phentermine (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Repaglinide (Compound)
Phentermine may lead to a major life threatening interaction when taken with Phenelzine and Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Phent... |
DB00543 | DB01364 | 87 | 22 | [
"DDInter82",
"DDInter650"
] | Amoxapine | Ephedrine | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Major | 2 | [
[
[
87,
25,
22
]
],
[
[
87,
6,
5214
],
[
5214,
45,
22
]
],
[
[
87,
21,
28680
],
[
28680,
60,
22
]
],
[
[
87,
63,
475
],
[
475,
23,
... | [
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ephedrine"
]
],
[
[
"Amoxapine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is bound by {v} (Compound)",
"Ephedrine"... | Amoxapine (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Ephedrine (Compound)
Amoxapine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Ephedrine (Compound)
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a ... |
DB00252 | DB00731 | 362 | 1,144 | [
"DDInter1460",
"DDInter1269"
] | Phenytoin | Nateglinide | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
362,
24,
1144
]
],
[
[
362,
64,
168
],
[
168,
24,
1144
]
],
[
[
362,
6,
1829
],
[
1829,
45,
1144
]
],
[
[
362,
21,
28787
],
[
28787,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib"... | Phenytoin may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Phenytoin (Compound) binds ALB (Gene) and ALB (Gene) is bound by Nateglinide (Compound)
Phenytoin (Compound) causes Dermatitis ... |
DB08881 | DB09065 | 868 | 760 | [
"DDInter1925",
"DDInter424"
] | Vemurafenib | Cobicistat | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
868,
24,
760
]
],
[
[
868,
62,
479
],
[
479,
23,
760
]
],
[
[
868,
24,
1627
],
[
1627,
23,
760
]
],
[
[
868,
23,
271
],
[
271,
2... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Vemurafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
... | Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidi... |
DB01177 | DB06788 | 77 | 1,616 | [
"DDInter904",
"DDInter864"
] | Idarubicin | Histrelin | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
77,
24,
1616
]
],
[
[
77,
62,
112
],
[
112,
23,
1616
]
],
[
[
77,
63,
1664
],
[
1664,
24,
1616
]
],
[
[
77,
24,
623
],
[
623,
24... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Idarubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Idarubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risp... |
DB00274 | DB00994 | 277 | 361 | [
"DDInter320",
"DDInter1277"
] | Cefmetazole | Neomycin | A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted. | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Moderate | 1 | [
[
[
277,
24,
361
]
],
[
[
277,
24,
1132
],
[
1132,
24,
361
]
],
[
[
277,
24,
1448
],
[
1448,
63,
361
]
],
[
[
277,
1,
1124
],
[
1124,
... | [
[
[
"Cefmetazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
]
],
[
[
"Cefmetazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gentamicin"
],
[
... | Cefmetazole may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin
Cefmetazole may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Stre... |
DB00633 | DB06282 | 614 | 516 | [
"DDInter520",
"DDInter1053"
] | Dexmedetomidine | Levocetirizine | An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
614,
24,
516
]
],
[
[
614,
63,
701
],
[
701,
24,
516
]
],
[
[
614,
24,
407
],
[
407,
63,
516
]
],
[
[
614,
24,
1219
],
[
1219,
2... | [
[
[
"Dexmedetomidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Dexmedetomidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
... | Dexmedetomidine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Dexmedetomidine may cause a moderate interaction that could exacerbate diseases when taken with Opium a... |
DB01261 | DB09129 | 170 | 625 | [
"DDInter1679",
"DDInter373"
] | Sitagliptin | Chromic chloride | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN). | Moderate | 1 | [
[
[
170,
24,
625
]
],
[
[
170,
23,
52
],
[
52,
24,
625
]
],
[
[
170,
63,
473
],
[
473,
24,
625
]
],
[
[
170,
24,
1296
],
[
1296,
63,... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromic chloride"
]
],
[
[
"Sitagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
],
... | Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Chromic chloride
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide a... |
DB00951 | DB01276 | 1,072 | 123 | [
"DDInter986",
"DDInter706"
] | Isoniazid | Exenatide | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1072,
24,
123
]
],
[
[
1072,
24,
1476
],
[
1476,
63,
123
]
],
[
[
1072,
62,
1573
],
[
1573,
24,
123
]
],
[
[
1072,
63,
1560
],
[
1560,... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Isoniazid may cause a minor interaction that can limit clinical effects when taken with Prednisone and Prednisone ... |
DB06603 | DB06802 | 39 | 282 | [
"DDInter1387",
"DDInter1280"
] | Panobinostat | Nepafenac (ophthalmic) | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Nepafenac is a monocarboxylic acid amide that is amfenac in which the carboxylic acid group has been converted into the corresponding carboxamide. It is a prodrug for amfenac, used in eye drops to treat pain and inflammation following cataract surgery. It has a role as a prodrug, a cyclooxygenase 2 inhibitor, a cycloox... | Moderate | 1 | [
[
[
39,
24,
282
]
],
[
[
39,
64,
886
],
[
886,
1,
282
]
],
[
[
39,
63,
307
],
[
307,
1,
282
]
],
[
[
39,
63,
1335
],
[
1335,
40,
... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nepafenac"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ketorolac"
],
[
"Ketorola... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Nepafenac
Panobinostat may lead to a major life threatening interaction when taken with Ketorolac and Ketorolac (Compound) resembles Nepafenac (Compound)
Panobinostat may cause a moderate interaction that could exacerbate disea... |
DB00280 | DB00681 | 494 | 1,287 | [
"DDInter575",
"DDInter85"
] | Disopyramide | Amphotericin B | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Moderate | 1 | [
[
[
494,
24,
1287
]
],
[
[
494,
21,
28897
],
[
28897,
60,
1287
]
],
[
[
494,
64,
600
],
[
600,
23,
1287
]
],
[
[
494,
24,
86
],
[
86,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
]
],
[
[
"Disopyramide",
"{u} (Compound) causes {v} (Side Effect)",
"Coma"
],
[
"Coma",
"{u} (Side Effect) is caused... | Disopyramide (Compound) causes Coma (Side Effect) and Coma (Side Effect) is caused by Amphotericin B (Compound)
Disopyramide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Amphotericin B
Disopyram... |
DB00902 | DB11823 | 104 | 858 | [
"DDInter1168",
"DDInter673"
] | Methdilazine | Esketamine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Eske... | Moderate | 1 | [
[
[
104,
24,
858
]
],
[
[
104,
24,
272
],
[
272,
24,
858
]
],
[
[
104,
63,
506
],
[
506,
24,
858
]
],
[
[
104,
40,
820
],
[
820,
24,... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Dextr... |
DB00776 | DB00792 | 1,335 | 832 | [
"DDInter1360",
"DDInter1878"
] | Oxcarbazepine | Tripelennamine | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
1335,
24,
832
]
],
[
[
1335,
40,
11233
],
[
11233,
1,
832
]
],
[
[
1335,
24,
100
],
[
100,
63,
832
]
],
[
[
1335,
24,
649
],
[
649,
... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Oxcarbazepine",
"{u} (Compound) resembles {v} (Compound)",
"Dimetacrine"
],
[
"Dimetacrine",
"{u} (Compou... | Oxcarbazepine (Compound) resembles Dimetacrine (Compound) and Dimetacrine (Compound) resembles Tripelennamine (Compound)
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when ... |
DB00046 | DB06788 | 1,179 | 1,616 | [
"DDInter940",
"DDInter864"
] | Insulin lispro | Histrelin | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
1179,
24,
1616
]
],
[
[
1179,
24,
1247
],
[
1247,
23,
1616
]
],
[
[
1179,
24,
1664
],
[
1664,
24,
1616
]
],
[
[
1179,
25,
739
],
[
739... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Risp... |
DB00734 | DB08875 | 1,664 | 1,618 | [
"DDInter1605",
"DDInter262"
] | Risperidone | Cabozantinib | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1664,
25,
1618
]
],
[
[
1664,
23,
112
],
[
112,
23,
1618
]
],
[
[
1664,
24,
1662
],
[
1662,
63,
1618
]
],
[
[
1664,
24,
480
],
[
480,
... | [
[
[
"Risperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Risperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Risperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric ac... |
DB00530 | DB00682 | 1,195 | 126 | [
"DDInter667",
"DDInter1951"
] | Erlotinib | Warfarin | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
1195,
24,
126
]
],
[
[
1195,
24,
1335
],
[
1335,
40,
126
]
],
[
[
1195,
63,
362
],
[
362,
24,
126
]
],
[
[
1195,
6,
3486
],
[
3486,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Warfarin (Compound)
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could... |
DB00475 | DB08900 | 1,119 | 1,162 | [
"DDInter355",
"DDInter1753"
] | Chlordiazepoxide | Teduglutide | An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. | Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that te... | Moderate | 1 | [
[
[
1119,
24,
1162
]
],
[
[
1119,
40,
1382
],
[
1382,
24,
1162
]
],
[
[
1119,
1,
1418
],
[
1418,
24,
1162
]
],
[
[
1119,
40,
1382
],
[
138... | [
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teduglutide"
]
],
[
[
"Chlordiazepoxide",
"{u} (Compound) resembles {v} (Compound)",
"Midazolam"
],
[
"Midazolam",
"{u} may caus... | Chlordiazepoxide (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Teduglutide
Chlordiazepoxide (Compound) resembles Estazolam (Compound) and Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Te... |
DB00959 | DB09237 | 1,486 | 1,586 | [
"DDInter1191",
"DDInter1045"
] | Methylprednisolone | Levamlodipine | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
1486,
24,
1586
]
],
[
[
1486,
63,
1648
],
[
1648,
24,
1586
]
],
[
[
1486,
24,
549
],
[
549,
24,
1586
]
],
[
[
1486,
40,
870
],
[
870,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleu... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00023 | DB00313 | 305 | 556 | [
"DDInter127",
"DDInter1913"
] | Asparaginase Escherichia coli | Valproic acid | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Moderate | 1 | [
[
[
305,
24,
556
]
],
[
[
305,
24,
1686
],
[
1686,
62,
556
]
],
[
[
305,
24,
168
],
[
168,
23,
556
]
],
[
[
305,
24,
267
],
[
267,
6... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valproic acid"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide and Temozolomide may cause a minor interaction that can limit clinical effects when taken with Valproic acid
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate dis... |
DB00366 | DB04837 | 1,594 | 649 | [
"DDInter600",
"DDInter407"
] | Doxylamine | Clofedanol | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1594,
24,
649
]
],
[
[
1594,
24,
1376
],
[
1376,
24,
649
]
],
[
[
1594,
74,
21
],
[
21,
24,
649
]
],
[
[
1594,
35,
1405
],
[
1405,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Doxylamine (Compound) resembles Amitriptyline (Compound) and Doxylamine may cause a moderate interacti... |
DB00220 | DB08901 | 798 | 1,468 | [
"DDInter1276",
"DDInter1492"
] | Nelfinavir | Ponatinib | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
798,
25,
1468
]
],
[
[
798,
25,
478
],
[
478,
24,
1468
]
],
[
[
798,
6,
12523
],
[
12523,
45,
1468
]
],
[
[
798,
7,
6717
],
[
6717,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may ... | Nelfinavir may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Nelfinavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Nelfinavir (Compound) upregulates HER... |
DB00031 | DB09079 | 20 | 1,496 | [
"DDInter1764",
"DDInter1296"
] | Tenecteplase | Nintedanib | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
20,
24,
1496
]
],
[
[
20,
25,
707
],
[
707,
24,
1496
]
],
[
[
20,
24,
1317
],
[
1317,
24,
1496
]
],
[
[
20,
64,
942
],
[
942,
24... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danapa... | Tenecteplase may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole ma... |
DB00472 | DB00816 | 758 | 1,674 | [
"DDInter758",
"DDInter1346"
] | Fluoxetine | Orciprenaline | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
758,
24,
1674
]
],
[
[
758,
21,
28921
],
[
28921,
60,
1674
]
],
[
[
758,
63,
1685
],
[
1685,
24,
1674
]
],
[
[
758,
24,
959
],
[
959,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Fluoxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is c... | Fluoxetine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Orciprenaline (Compound)
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00814 | DB00877 | 1,171 | 629 | [
"DDInter1143",
"DDInter1678"
] | Meloxicam | Sirolimus | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Major | 2 | [
[
[
1171,
25,
629
]
],
[
[
1171,
6,
8374
],
[
8374,
45,
629
]
],
[
[
1171,
21,
29203
],
[
29203,
60,
629
]
],
[
[
1171,
63,
167
],
[
167,
... | [
[
[
"Meloxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Meloxicam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sirolimus"... | Meloxicam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sirolimus (Compound)
Meloxicam (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Sirolimus (Compound)
Meloxicam may cause a moderate interaction that could exacer... |
DB01015 | DB05812 | 1,247 | 1,374 | [
"DDInter1724",
"DDInter8"
] | Sulfamethoxazole | Abiraterone | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Minor | 0 | [
[
[
1247,
23,
1374
]
],
[
[
1247,
6,
1829
],
[
1829,
45,
1374
]
],
[
[
1247,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
1247,
62,
112
],
[
11... | [
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
]
],
[
[
"Sulfamethoxazole",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compou... | Sulfamethoxazole (Compound) binds ALB (Gene) and ALB (Gene) is bound by Abiraterone (Compound)
Sulfamethoxazole (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Metroni... |
DB00694 | DB01218 | 51 | 1,493 | [
"DDInter485",
"DDInter852"
] | Daunorubicin | Halofantrine | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
51,
25,
1493
]
],
[
[
51,
6,
8374
],
[
8374,
45,
1493
]
],
[
[
51,
18,
5998
],
[
5998,
46,
1493
]
],
[
[
51,
18,
2183
],
[
2183,
... | [
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Daunorubicin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"H... | Daunorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Halofantrine (Compound)
Daunorubicin (Compound) downregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Halofantrine (Compound)
Daunorubicin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Halofantrine (Compound)
... |
DB00468 | DB04953 | 1,424 | 495 | [
"DDInter1557",
"DDInter708"
] | Quinine | Ezogabine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Moderate | 1 | [
[
[
1424,
24,
495
]
],
[
[
1424,
21,
28787
],
[
28787,
60,
495
]
],
[
[
1424,
23,
1135
],
[
1135,
62,
495
]
],
[
[
1424,
23,
112
],
[
112,... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Quinine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by... | Quinine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ezogabine (Compound)
Quinine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ezogabine
Quinine ... |
DB00903 | DB01105 | 1,680 | 222 | [
"DDInter686",
"DDInter1665"
] | Etacrynic acid | Sibutramine | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1680,
24,
222
]
],
[
[
1680,
21,
29209
],
[
29209,
60,
222
]
],
[
[
1680,
24,
659
],
[
659,
63,
222
]
],
[
[
1680,
24,
1376
],
[
1376,... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Etacrynic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) ... | Etacrynic acid (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Sibutramine (Compound)
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00877 | DB01227 | 629 | 1,301 | [
"DDInter1678",
"DDInter1043"
] | Sirolimus | Levacetylmethadol | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Moderate | 1 | [
[
[
629,
24,
1301
]
],
[
[
629,
63,
494
],
[
494,
1,
1301
]
],
[
[
629,
6,
8374
],
[
8374,
45,
1301
]
],
[
[
629,
24,
1532
],
[
1532,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
],
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Levacetylmethadol (Compound)
Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levacetylmethadol (Compound)
Sirolimus may cause a moderate interaction that co... |
DB00607 | DB09293 | 1,249 | 116 | [
"DDInter1256",
"DDInter954"
] | Nafcillin | Iodide I-131 | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
1249,
24,
116
]
],
[
[
1249,
25,
126
],
[
126,
24,
116
]
],
[
[
1249,
24,
978
],
[
978,
24,
116
]
],
[
[
1249,
25,
1019
],
[
1019,
... | [
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Nafcillin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
... | Nafcillin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Praziquantel and Praziquantel may cause ... |
DB00539 | DB00637 | 11 | 1,557 | [
"DDInter1837",
"DDInter128"
] | Toremifene | Astemizole | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Major | 2 | [
[
[
11,
25,
1557
]
],
[
[
11,
25,
1568
],
[
1568,
64,
1557
]
],
[
[
11,
6,
8374
],
[
8374,
45,
1557
]
],
[
[
11,
7,
9915
],
[
9915,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Astemizole"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimozide"
],
[
"Pimozide",
"{u} may l... | Toremifene may lead to a major life threatening interaction when taken with Pimozide and Pimozide may lead to a major life threatening interaction when taken with Astemizole
Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Astemizole (Compound)
Toremifene (Compound) upregulates LIPA (Gene) and LI... |
DB11837 | DB11979 | 1,297 | 1,320 | [
"DDInter1351",
"DDInter625"
] | Osilodrostat | Elagolix | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1297,
24,
1320
]
],
[
[
1297,
63,
608
],
[
608,
23,
1320
]
],
[
[
1297,
62,
271
],
[
271,
23,
1320
]
],
[
[
1297,
63,
79
],
[
79,
... | [
[
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Elagolix
Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron... |
DB01234 | DB06718 | 1,220 | 1,687 | [
"DDInter513",
"DDInter1709"
] | Dexamethasone | Stanozolol | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes. | Moderate | 1 | [
[
[
1220,
24,
1687
]
],
[
[
1220,
24,
1546
],
[
1546,
1,
1687
]
],
[
[
1220,
63,
1561
],
[
1561,
40,
1687
]
],
[
[
1220,
74,
155
],
[
155,... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stanozolol"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Stanozolol (Compound)
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resemb... |
DB00835 | DB06702 | 100 | 573 | [
"DDInter245",
"DDInter731"
] | Brompheniramine | Fesoterodine | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
100,
24,
573
]
],
[
[
100,
24,
211
],
[
211,
1,
573
]
],
[
[
100,
63,
494
],
[
494,
1,
573
]
],
[
[
100,
6,
12523
],
[
12523,
45... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Feso... |
DB00295 | DB06204 | 475 | 768 | [
"DDInter1244",
"DDInter1746"
] | Morphine | Tapentadol | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Major | 2 | [
[
[
475,
25,
768
]
],
[
[
475,
6,
12523
],
[
12523,
45,
768
]
],
[
[
475,
21,
29332
],
[
29332,
60,
768
]
],
[
[
475,
24,
1123
],
[
1123,
... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tapentadol"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Tapentadol"... | Morphine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tapentadol (Compound)
Morphine (Compound) causes Drug withdrawal syndrome (Side Effect) and Drug withdrawal syndrome (Side Effect) is caused by Tapentadol (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00741 | DB11714 | 167 | 1,316 | [
"DDInter885",
"DDInter610"
] | Hydrocortisone | Durvalumab | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Moderate | 1 | [
[
[
167,
24,
1316
]
],
[
[
167,
62,
1461
],
[
1461,
23,
1316
]
],
[
[
167,
23,
1114
],
[
1114,
23,
1316
]
],
[
[
167,
24,
1136
],
[
1136,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
]
],
[
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
... | Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Durvalumab
Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc... |
DB00631 | DB11943 | 372 | 255 | [
"DDInter405",
"DDInter495"
] | Clofarabine | Delafloxacin | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Minor | 0 | [
[
[
372,
23,
255
]
],
[
[
372,
63,
377
],
[
377,
23,
255
]
],
[
[
372,
24,
995
],
[
995,
23,
255
]
],
[
[
372,
35,
1224
],
[
1224,
2... | [
[
[
"Clofarabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
],
[
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea and Hydro... |
DB01583 | DB09043 | 624 | 135 | [
"DDInter1075",
"DDInter36"
] | Liotrix | Albiglutide | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal s... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
624,
24,
135
]
],
[
[
624,
63,
126
],
[
126,
23,
135
]
],
[
[
624,
62,
467
],
[
467,
23,
135
]
],
[
[
624,
63,
176
],
[
176,
24,... | [
[
[
"Liotrix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Liotrix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Wa... | Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Liotrix may cause a minor interaction that can limit clinical effects when taken with Simvastatin and Simvastatin may ca... |
DB00059 | DB00685 | 1,560 | 1,299 | [
"DDInter1404",
"DDInter1887"
] | Pegaspargase | Trovafloxacin | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Moderate | 1 | [
[
[
1560,
24,
1299
]
],
[
[
1560,
24,
328
],
[
328,
62,
1299
]
],
[
[
1560,
63,
816
],
[
816,
23,
1299
]
],
[
[
1560,
24,
552
],
[
552,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trovafloxacin"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Gemtuzum... |
DB00549 | DB00813 | 522 | 704 | [
"DDInter1955",
"DDInter722"
] | Zafirlukast | Fentanyl | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Major | 2 | [
[
[
522,
25,
704
]
],
[
[
522,
23,
307
],
[
307,
1,
704
]
],
[
[
522,
63,
194
],
[
194,
40,
704
]
],
[
[
522,
24,
1322
],
[
1322,
40... | [
[
[
"Zafirlukast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fentanyl"
]
],
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
... | Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Fentanyl (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Fentanyl (Compound)
Zafi... |
DB09082 | DB09564 | 659 | 1,296 | [
"DDInter1934",
"DDInter930"
] | Vilanterol | Insulin degludec | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
659,
24,
1296
]
],
[
[
659,
64,
17
],
[
17,
24,
1296
]
],
[
[
659,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
659,
62,
175
],
[
175,
... | [
[
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Vilanterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol... | Vilanterol may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may caus... |
DB01263 | DB08816 | 859 | 578 | [
"DDInter1494",
"DDInter1802"
] | Posaconazole | Ticagrelor | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Major | 2 | [
[
[
859,
25,
578
]
],
[
[
859,
6,
4973
],
[
4973,
45,
578
]
],
[
[
859,
21,
28646
],
[
28646,
60,
578
]
],
[
[
859,
25,
1135
],
[
1135,
... | [
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
]
],
[
[
"Posaconazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Ticag... | Posaconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Posaconazole (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Posaconazole may lead ... |
DB00307 | DB00381 | 1,101 | 376 | [
"DDInter202",
"DDInter79"
] | Bexarotene | Amlodipine | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Moderate | 1 | [
[
[
1101,
24,
376
]
],
[
[
1101,
63,
1428
],
[
1428,
1,
376
]
],
[
[
1101,
24,
409
],
[
409,
1,
376
]
],
[
[
1101,
24,
1081
],
[
1081,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amlodipine"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Amlodipine (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine (Compound) resembles Amlodipine (Compound)
... |
DB01246 | DB11160 | 820 | 337 | [
"DDInter45",
"DDInter1459"
] | Alimemazine | Phenyltoloxamine | A phenothiazine derivative that is used as an antipruritic. | Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the... | Moderate | 1 | [
[
[
820,
24,
337
]
],
[
[
820,
23,
771
],
[
771,
62,
337
]
],
[
[
820,
63,
1594
],
[
1594,
24,
337
]
],
[
[
820,
24,
1511
],
[
1511,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],... | Alimemazine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Phenyltoloxamine
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine ... |
DB00014 | DB05316 | 521 | 749 | [
"DDInter839",
"DDInter1467"
] | Goserelin | Pimavanserin | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Moderate | 1 | [
[
[
521,
24,
749
]
],
[
[
521,
23,
112
],
[
112,
23,
749
]
],
[
[
521,
24,
1264
],
[
1264,
24,
749
]
],
[
[
521,
24,
594
],
[
594,
6... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimavanserin"
]
],
[
[
"Goserelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Goserelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pimavanserin
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin... |
DB00679 | DB00981 | 684 | 1,528 | [
"DDInter1796",
"DDInter1463"
] | Thioridazine | Physostigmine (ophthalmic) | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. | Moderate | 1 | [
[
[
684,
24,
1528
]
],
[
[
684,
21,
28658
],
[
28658,
60,
1528
]
],
[
[
684,
40,
508
],
[
508,
24,
1528
]
],
[
[
684,
24,
1511
],
[
1511,
... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Thioridazine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Thioridazine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Physostigmine (Compound)
Thioridazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate inte... |
DB00609 | DB09268 | 595 | 1,662 | [
"DDInter694",
"DDInter1464"
] | Ethionamide | Picosulfuric acid | A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
595,
24,
1662
]
],
[
[
595,
63,
597
],
[
597,
24,
1662
]
],
[
[
595,
24,
770
],
[
770,
24,
1662
]
],
[
[
595,
24,
1434
],
[
1434,
... | [
[
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
... | Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Th... |
DB00396 | DB09045 | 989 | 52 | [
"DDInter1529",
"DDInter607"
] | Progesterone | Dulaglutide | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in var... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
989,
24,
52
]
],
[
[
989,
24,
170
],
[
170,
23,
52
]
],
[
[
989,
24,
609
],
[
609,
24,
52
]
],
[
[
989,
40,
870
],
[
870,
24,
... | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin a... |
DB00448 | DB06626 | 1,215 | 263 | [
"DDInter1022",
"DDInter147"
] | Lansoprazole | Axitinib | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Minor | 0 | [
[
[
1215,
23,
263
]
],
[
[
1215,
40,
660
],
[
660,
23,
263
]
],
[
[
1215,
24,
1335
],
[
1335,
24,
263
]
],
[
[
1215,
63,
529
],
[
529,
... | [
[
[
"Lansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Axitinib"
]
],
[
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a min... | Lansoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction ... |
DB05679 | DB11569 | 1,683 | 1,093 | [
"DDInter1907",
"DDInter1003"
] | Ustekinumab | Ixekizumab | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Moderate | 1 | [
[
[
1683,
24,
1093
]
],
[
[
1683,
23,
1114
],
[
1114,
23,
1093
]
],
[
[
1683,
62,
1461
],
[
1461,
23,
1093
]
],
[
[
1683,
63,
608
],
[
608... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Ustekinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
... | Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ixekizumab
Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin... |
DB00099 | DB09570 | 440 | 1,480 | [
"DDInter735",
"DDInter1002"
] | Filgrastim | Ixazomib | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
440,
24,
1480
]
],
[
[
440,
63,
268
],
[
268,
24,
1480
]
],
[
[
440,
24,
310
],
[
310,
24,
1480
]
],
[
[
440,
24,
110
],
[
110,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with C... |
DB00582 | DB08895 | 1,622 | 976 | [
"DDInter1946",
"DDInter1825"
] | Voriconazole | Tofacitinib | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
1622,
25,
976
]
],
[
[
1622,
24,
660
],
[
660,
24,
976
]
],
[
[
1622,
25,
214
],
[
214,
63,
976
]
],
[
[
1622,
25,
868
],
[
868,
... | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Eso... | Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Voriconazole may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatin... |
DB00620 | DB00705 | 175 | 441 | [
"DDInter1855",
"DDInter496"
] | Triamcinolone | Delavirdine | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Major | 2 | [
[
[
175,
25,
441
]
],
[
[
175,
6,
8374
],
[
8374,
45,
441
]
],
[
[
175,
21,
28644
],
[
28644,
60,
441
]
],
[
[
175,
40,
1220
],
[
1220,
... | [
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
]
],
[
[
"Triamcinolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"... | Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Delavirdine (Compound)
Triamcinolone (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Delavirdine (Compound)
Triamcinolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interac... |
DB00549 | DB01039 | 522 | 535 | [
"DDInter1955",
"DDInter718"
] | Zafirlukast | Fenofibrate | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993. | Moderate | 1 | [
[
[
522,
24,
535
]
],
[
[
522,
6,
3486
],
[
3486,
45,
535
]
],
[
[
522,
21,
28921
],
[
28921,
60,
535
]
],
[
[
522,
24,
473
],
[
473,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibrate"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound... | Zafirlukast (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Fenofibrate (Compound)
Zafirlukast (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Fenofibrate (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide an... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.